Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156253 | 0.86 | ALDH1A1 (0.60) | KMT2AALDH1A1CA12CA1CA2 | |
| SCHEMBL159143 | 0.85 | TDP1 (0.44) | KMT2AALDH1A1TSHRCA12CA1 | |
| SCHEMBL5961640 | 0.83 | BCL2L1 (0.52) | KMT2APKMALDH1A1TSHRBCL2L1 | |
| SCHEMBL27996243 | 0.83 | POLB (0.63) | KMT2APKMALDH1A1TSHRBCL2L1 | |
| SCHEMBL851008 | 0.83 | ERCC1 (0.60) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL20999134 | 0.82 | BCL2L1 (0.53) | KMT2APKMALDH1A1TSHRBCL2L1 | |
| Water SCHEMBL9710740 | 0.81 | ERCC1 (0.58) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL12862656 | 0.79 | BCL2L1 (0.58) | KMT2APKMALDH1A1TSHRBCL2L1 | |
| SCHEMBL15933411 | 0.79 | ALDH1A1 (0.53) | KMT2AALDH1A1BCL2L1MCL1CA12 | |
| SCHEMBL1930853 | 0.79 | EGFR (0.53) | KMT2AALDH1A1TSHRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938106-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2024-03-26 | — | — | US | claimed |
| US-20230038631-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-02-09 | — | — | US | claimed |
| US-11304917-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-04-19 | — | — | US | claimed |
| US-20210251928-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIVERSITY | 2021-08-19 | — | — | US | claimed |
| WO-2017142543-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2017-08-24 | — | — | WO | claimed |
| US-20110263652-A1 | Treatment and/or Prevention of Inner Ear Conditions by Modulation of a Metabotropic Glutamate Receptor | HOUSE EAR INSTITUTE (US) | 2011-10-27 | — | — | US | claimed |
| EP-2344151-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | claimed |
| JP-2003528136-A | — | — | 2003-09-24 | — | — | JP | claimed |
| EP-1274417-A2 | TREATMENT OF MOVEMENT DISORDERS WITH METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | Motac Neuroscience Limited (GB) | 2003-01-15 | — | — | EP | claimed |
| WO-2001072291-A2 | TREATMENT OF MOVEMENT DISORDERS WITH METABOTROPIC GLUTAMATE RECEPTOR ANTAGONIST | THE VICTORIA UNIVERSITY OF MANCHESTER (GB) | 2001-10-04 | — | — | WO | claimed |
| US-6197820-B1 | METABOTROPIC GLUTAMATE RECEPTOR AGONIST/ANTAGONIST (S)-4-CARBOXYPHENYLGLYCINE (S-4CPG), POTENTLY AND SELECTIVELY INHIBITED GLUTAMATE RELEASE FROM GLIOMA CELLS AND THEREBY PREVENTED NEUROTOXICITY, INHIBIT RELEASE OF TOXIC LEVELS OF | UAB RESEARCH FOUNDATION | 2001-03-06 | — | — | US | claimed |
| WO-2000062771-A1 | USES OF PHENYLGLYCINE DERIVATIVES | THE UAB RESEARCH FOUNDATION (US) | 2000-10-26 | — | — | WO | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| EP-0783577-A1 | CHIMERIC RECEPTORS AND METHODS FOR IDENTIFYING COMPOUNDS ACTIVE AT METABOTROPIC GLUTAMATE RECEPTORS AND THE USE OF SUCH COMPOUNDS IN THE TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997022251-A1 | COMPOSITIONS FOR MODULATING INTRACELLULAR INOSITOL TRISPHOSPHATE CONCENTRATION AND USES THEREOF | AYURCORE, INC. (US) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997005252-A2 | CHIMERIC RECEPTORS AND METHODS FOR IDENTIFYING COMPOUNDS ACTIVE AT METABOTROPIC GLUTAMATE RECEPTORS AND THE USE OF SUCH COMPOUNDS IN THE TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1997-02-13 | — | — | WO | disclosed |
| WO-1996005818-A1 | METHODS AND COMPOUNDS ACTIVE AT METABOTROPIC GLUTAMATE RECEPTORS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | KMT2A 4260/4885PKM 3467/4885ALDH1A1 4784/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | KMT2A 3984/4885PKM 3650/4885ALDH1A1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.